- Home
- CARS vs ABCL Comparison
CARS vs ABCL Comparison
Compare CARS & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- ABCL
- Stock Information
- Founded
- CARS 1998
- ABCL 2012
- Country
- CARS United States
- ABCL Canada
- Employees
- CARS N/A
- ABCL N/A
- Industry
- CARS Motor Vehicles
- ABCL Biotechnology: Pharmaceutical Preparations
- Sector
- CARS Consumer Discretionary
- ABCL Health Care
- Exchange
- CARS Nasdaq
- ABCL Nasdaq
- Market Cap
- CARS 723.4M
- ABCL 772.9M
- IPO Year
- CARS 2017
- ABCL 2020
- Fundamental
- Price
- CARS $10.06
- ABCL $2.01
- Analyst Decision
- CARS Buy
- ABCL Buy
- Analyst Count
- CARS 5
- ABCL 3
- Target Price
- CARS $18.50
- ABCL $7.50
- AVG Volume (30 Days)
- CARS 804.4K
- ABCL 4.0M
- Earning Date
- CARS 05-08-2025
- ABCL 05-08-2025
- Dividend Yield
- CARS N/A
- ABCL N/A
- EPS Growth
- CARS N/A
- ABCL N/A
- EPS
- CARS 0.69
- ABCL N/A
- Revenue
- CARS $718,000,000.00
- ABCL $28,833,000.00
- Revenue This Year
- CARS $5.36
- ABCL N/A
- Revenue Next Year
- CARS $4.28
- ABCL $36.62
- P/E Ratio
- CARS $14.60
- ABCL N/A
- Revenue Growth
- CARS 2.24
- ABCL N/A
- 52 Week Low
- CARS $9.87
- ABCL $1.89
- 52 Week High
- CARS $21.24
- ABCL $4.34
- Technical
- Relative Strength Index (RSI)
- CARS 29.50
- ABCL 33.61
- Support Level
- CARS $11.58
- ABCL $2.45
- Resistance Level
- CARS $12.05
- ABCL $2.64
- Average True Range (ATR)
- CARS 0.39
- ABCL 0.14
- MACD
- CARS -0.06
- ABCL -0.06
- Stochastic Oscillator
- CARS 18.50
- ABCL 3.60
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.